Literature DB >> 395845

Results of therapy in systemic nocardiosis.

P J Geiseler, B R Andersen.   

Abstract

The effect of therapy on the clinical course of pleuropulmonary and systemic Nocardia asteroides disease in 78 reported cases was analyzed. All patients were treated with drugs. In 72 cases sulfonamides alone or in combination with other antibiotics was given; 45 patients underwent surgical procedures. The extent of disease had a bearing on survival as only 3 of 39 patients (7.6%) with isolated pleuropulmonary involvement died. These fatalities occurred among the 16 patients of this group who received immunosuppressive drugs. One of 12 patients (8.3%) with suppurative foci other than brain abscess and pleuropulmonary nocardiosis died, whereas the fatality rate of cases with nocardial brain abscess was 47.8%. Thirty-one patients relapsed or had progression of disease while receiving drugs for nocardiosis, 30 of them within the first three months. Prolonged post-treatment observation is essential in the management of nocardiosis as four patients relapsed after drug therapy was discountinued, three of them between six and eight months. Although there was no significant difference in the survival of patients treated with only drugs when compared to those who also had surgery, no fatalities occurred among those medically treated for six months or longer (p = .0091).

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 395845     DOI: 10.1097/00000441-197911000-00001

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  16 in total

1.  First report of a brain abscess caused by Nocardia veterana.

Authors:  J E Arends; A M Stemerding; S P Vorst; A J de Neeling; A J L Weersink
Journal:  J Clin Microbiol       Date:  2011-10-12       Impact factor: 5.948

Review 2.  Clinical and clinical laboratory aspects of nocardial infection.

Authors:  D A Stevens
Journal:  J Hyg (Lond)       Date:  1983-12

3.  In vitro activities of linezolid against multiple Nocardia species.

Authors:  B A Brown-Elliott; S C Ward; C J Crist; L B Mann; R W Wilson; R J Wallace
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

Review 4.  Nocardia infection in splenectomized patients: case reports and a review of the literature.

Authors:  E A Abdi; J C Ding; I A Cooper
Journal:  Postgrad Med J       Date:  1987-06       Impact factor: 2.401

5.  In vitro antimicrobial susceptibilities of Nocardia species.

Authors:  N Khardori; R Shawar; R Gupta; B Rosenbaum; K Rolston
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

6.  Therapy of experimental cerebral nocardiosis with imipenem, amikacin, trimethoprim-sulfamethoxazole, and minocycline.

Authors:  M E Gombert; T M Aulicino; L duBouchet; G E Silverman; W M Sheinbaum
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

Review 7.  Nocardia species: host-parasite relationships.

Authors:  B L Beaman; L Beaman
Journal:  Clin Microbiol Rev       Date:  1994-04       Impact factor: 26.132

8.  Amikacin-containing regimens for treatment of nocardiosis in immunocompromised patients.

Authors:  F W Goldstein; B Hautefort; J F Acar
Journal:  Eur J Clin Microbiol       Date:  1987-04       Impact factor: 3.267

9.  A fatal case of Nocardia otitidiscaviarum pulmonary infection and brain abscess: taxonomic characterization by molecular techniques.

Authors:  Ana Isabel Pelaez; Maria del Mar Garcia-Suarez; Angel Manteca; Ovidio Melon; Carlos Aranaz; Rafael Cimadevilla; Francisco Javier Mendez; Fernando Vazquez
Journal:  Ann Clin Microbiol Antimicrob       Date:  2009-04-14       Impact factor: 3.944

Review 10.  Abscess of adrenal gland caused by disseminated subacute Nocardia farcinica pneumonia. A case report and mini-review of the literature.

Authors:  Michael Tachezy; Philipp Simon; Corina Ilchmann; Yogesh K Vashist; Jakob R Izbicki; Karim A Gawad
Journal:  BMC Infect Dis       Date:  2009-12-02       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.